0001654954-20-005979.txt : 20200526 0001654954-20-005979.hdr.sgml : 20200526 20200526172335 ACCESSION NUMBER: 0001654954-20-005979 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200526 DATE AS OF CHANGE: 20200526 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-196243 FILM NUMBER: 20911854 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 424B3 1 cvm_424b3.htm 424B3 cvm_424b3
 
PROSPECTUS SUPPLEMENT
Filed pursuant to Rule 424(b)(3)
(To Prospectus Supplement
Registration No. 333-196243
dated May 22, 2015)
 
CEL-SCI CORPORATION
Series V Warrants
 
 
 
The Company's Series V warrants expire on May 28, 2020 at an exercise price of $19.75. On May 26, 2020, the Company lowered the exercise price of its Series V warrants to $13.75 per share and extended the expiration date of the warrants to June 25, 2020. The Series V warrants were originally issued as part of a financing on May 28, 2015. For each Series V warrant exercised on or before June 10, 2020 the former holder of the Series V warrant will receive one Series XX warrant. Every Series XX warrant will allow the holder to purchase one share of the Company’s common stock at a price of $18.00 per share at any time on or before September 10, 2020. For each Series V warrant exercised after June 10, 2020 but on or before June 25, 2020 the former holder of the Series V warrant will receive one Series YY warrant. Every two Series YY warrants will allow the holder to purchase one share of the Company’s common stock at a price of $20.00 per share at any time on or before September 25, 2020.
 
Due to regulations of the Securities and Exchange Commission, only accredited investors will be entitled to receive the Series XX or Series YY warrants.
 
 
 
 
 
 
 
 
 
Prospectus Supplement dated May 26, 2020